title: [Efficiency of treatment of uveitis with the drug superlymph].
abstract: Comparative analysis of the results of combination treatment using superlymph and the conventional therapy in 17 and 52 patients, respectively, demonstrated that the combination therapy showed a marked clinical and immunological effect. The use of superlymph in local therapy, unlike the conventional etiopathogenetic treatment, resulted in an earlier decrease and arrest of an inflammatory reaction, in recovery of visual functions (for 2-4 day). Superlymph was found to be well tolerated and to cause no subjective discomfort or complications. Its immunomodulating effect was to normalize the count of T-theophylline-sensitive lymphocytes and, accordingly, the immunoregulation index, the serum concentrations of serum IgG, IgA, particularly IgE, and the phagocytic function of neutrophils. Superlymph exerted a pronounced effect on the systemic and local cytokine status, by decreasing the hypersecretion of cytokines, the regulators of inflammation. The clinical and immunological effects and good tolerability of superlymph permit it to recommend for its wide use in therapy of inflammatory eye diseases.
authors.forename: L E
authors.initials: LE
authors.lastname: Teplinskaia
authors.forename: N S
authors.initials: NS
authors.lastname: Filichkina
authors.forename: K S
authors.initials: KS
authors.lastname: Matevosova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008263:Macrophage Migration-Inhibitory Factors / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D016207:Cytokines; D007136:Immunoglobulins; D007155:Immunologic Factors; D008263:Macrophage Migration-Inhibitory Factors; D013806:Theophylline